Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia

Clinical Endocrinology

Volumn 73, Issue 3, 2010, Pages 369-374

  Tan, Tricia ^a,b   Cabrita, Ines Z ^c   Hensman, Davina ^a   Grogono, Joanna ^a   Dhillo, Waljit S ^a,b   Baynes, Kevin C ^a,d   Eliahoo, Joseph ^a   Meeran, Karim ^a,b   Robinson, Stephen ^b   Nihoyannopoulos, Petros ^c   Martin, Niamh M ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; PROLACTIN;

ADULT; AGE DISTRIBUTION; AORTA VALVE REGURGITATION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HEART LEFT VENTRICLE WALL; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; MORPHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEX DIFFERENCE; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; ANTIPARKINSON AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; HEART VALVE DISEASES; HEART VALVES; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 77955719568     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03827.x     Document Type: Article

References (31)

1. Sherlock, M., Toogood, A.A. Steeds, R. (2009) Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart, 95, 522 523.
2. Schade, R., Andersohn, F., Suissa, S. et al. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29 38.
3. Zanettini, R., Antonini, A., Gatto, G. et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine, 356, 39 46.
4. Roth, B.L. (2007) Drugs and valvular heart disease. New England Journal of Medicine, 356, 6 9.
5. Lancellotti, P., Livadariu, E., Markov, M. et al. (2008) Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology, 159, 1 5.
6. Bogazzi, F., Buralli, S., Manetti, L. et al. (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice, 62, 1864 1869.
7. Vallette, S., Serri, K., Rivera, J. et al. (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary, 12, 153 157.
8. Wakil, A., Rigby, A.S., Clark, A.L. et al. (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology, 159, R11 R14.
9. Herring, N., Szmigielski, C., Becher, H. et al. (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology, 70, 104 108.
10. Nachtigall, L.B., Valassi, E., Lo, J. et al. (2009) Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical Endocrinology, 72, 53 58.
11. Kars, M., Delgado, V., Holman, E.R. et al. (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. Journal of Clinical Endocrinology and Metabolism, 93, 3348 3356.
12. Colao, A., Galderisi, M., Di Sarno, A. et al. (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism, 93, 3777 3784.
13. Devin, J.K., Lakhani, V.T., Byrd, B.F. et al. (2008) Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocrine Practice, 14, 672 677.
14. European Medicines Agency (2008) EMEA Recommends New Warnings and Contraindications for Ergot-Derived Dopamine Agonists. ed. European Medicines Agency, London.
15. Medicines and Healthcare products Regulatory Agency (2008) Drug Safety Update: Ergot-derived Dopamine Agonists: Risk of Fibrotic Reactions in Chronic Endocrine Uses. London.
16. Kars, M., Souverein, P.C., Herings, R.M. et al. (2009) Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 94, 2729 2734.
17. Singh, J.P., Evans, J.C., Levy, D. et al. (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). American Journal of Cardiology, 83, 897 902.
18. Martin, N.M., Tan, T. Meeran, K. (2009) Dopamine agonists and hyperprolactinaemia. BMJ, 338, b381.
19. Molitch, M.E. (2008) The cabergoline-resistant prolactinoma patient: new challenges. Journal of Clinical Endocrinology and Metabolism, 93, 4643 4645.
20. Gottdiener, J.S., Bednarz, J., Devereux, R. et al. (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. Journal of the American Society of Echocardiography, 17, 1086 1119.
21. Lang, R.M., Bierig, M., Devereux, R.B. et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography, 18, 1440 1463.
22. Evangelista, A., Flachskampf, F., Lancellotti, P. et al. (2008) European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. European Journal of Echocardiography, 9, 438 448.
23. Nagueh, S.F., Appleton, C.P., Gillebert, T.C. et al. (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography, 22, 107 133.
24. Zoghbi, W.A., Enriquez-Sarano, M., Foster, E. et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. Journal of the American Society of Echocardiography, 16, 777 802.
25. Baumgartner, H., Hung, J., Bermejo, J. et al. (2009) Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. European Journal of Echocardiography, 10, 1 25.
26. Yoshida, K., Yoshikawa, J., Shakudo, M. et al. (1988) Color Doppler evaluation of valvular regurgitation in normal subjects. Circulation, 78, 840 847.
27. Vignola, P.A., Bloch, A., Kaplan, A.D. et al. (1977) Interobserver variability in echocardiography. Journal of Clinical Ultrasound, 5, 238 242.
28. Van Camp, G., Flamez, A., Cosyns, B. et al. (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet, 363, 1179 1183.
29. Timek, T.A. Miller, D.C. (2001) Experimental and clinical assessment of mitral annular area and dynamics: what are we actually measuring? Annals of Thoracic Surgery, 72, 966 974.
30. Colao, A., Di Sarno, A., Cappabianca, P. et al. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New England Journal of Medicine, 349, 2023 2033.
31. Oeda, T., Masaki, M., Yamamoto, K. et al. (2009) High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. Journal of Neural Transmission, 116, 171 178.